Form 8-K - Current report:
SEC Accession No. 0000950170-24-014944
Filing Date
2024-02-14
Accepted
2024-02-14 08:00:11
Documents
12
Period of Report
2024-02-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K inkt-20240212.htm   iXBRL 8-K 37940
  Complete submission text file 0000950170-24-014944.txt   155003

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20240212.xsd EX-101.SCH 25842
13 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20240212_htm.xml XML 4885
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 24632425
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)